Evidence map›Paper›PMID 40557796›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Gut Parabacteroides distasonis-derived Indole-3-Acetic Acid Promotes Phospholipid Remodeling and Enhances Ferroptosis Sensitivity via the AhR-FASN Axis in Bladder Cancer.

Weijia Li, Wentai Shangguan, Wenxue Huang, Jie Zhao, Yuexuan Zhu, Ming Xie, Yao Yu, Qishen Yang, Jun Zheng, Lin Yang and 7 more

Erratum issuedAbstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Induction of ferroptosis in prostate cancer by CCDC7Cell death and differentiation · 2026
    Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. The Urinary Microbiota and the Gut-Bladder Axis in Bladder Cancer.International journal of molecular sciences · 2025
    Review
  14. Article
  15. Review
  16. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Weijia LiDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, P. R. China.ORCID https://orcid.org/0009-0005-9665-8206
Wentai ShangguanDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, P. R. China.
Wenxue HuangDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, P. R. China.
Jie ZhaoNMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 510515, China.
Yuexuan ZhuDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, P. R. China.
Ming XieDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, P. R. China.
Yao YuDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, P. R. China.
Qishen YangDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, P. R. China.
Jun ZhengDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, P. R. China.
Lin YangDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, P. R. China.
Qi SunDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, P. R. China.
Leqian LiDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, P. R. China.
Xinhang ShiDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, P. R. China.
Yongyuan XiaoDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, P. R. China.
Hai HuangDepartment of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China.
Bisheng ChengDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, P. R. China.
Peng WuDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, P. R. China.ORCID https://orcid.org/0009-0004-9171-9658

Funding

Guangdong Provincial Key Research and Development Program 2023B1111030006Guangzhou Key Research and Development Program 2023B03J1245National Natural Science Foundation of China 82370782National Natural Science Foundation of China 82472902President Foundation of Nanfang Hospital Southern Medical University 2024A028
6 · The paper itself

Abstract

The development of bladder cancer is a complex, multistep process influenced by both genetic and environmental factors, but its exact etiology remains unclear. Increasing evidence suggests that gut microbiota dysregulation can impact the initiation and progression of cancers, including colorectal cancer, breast cancer, and pancreatic cancer. This study observes that the beneficial gut bacterium Parabacteroides distasonis (P. distasonis) is significantly decreased in bladder cancer patients, and its low abundance is strongly associated with poor prognosis. P. distasonis is a next-generation probiotic which plays a vital role in human health. Furthermore, this work finds that P. distasonis culture medium inhibits metastasis and proliferation of bladder cancer cells in vitro and in vivo. This work identifies that indole-3-acetic acid (3-IAA) produced by P. distasonis exerting similar tumor-suppressive effects. Mechanistically, 3-IAA activates the aryl hydrocarbon receptor (AhR), which in turn downregulates fatty acid synthase (FASN) transcription in bladder cancer cells. Notably, the reduction of FASN expression decreases the ratio of MUFAs to PUFAs, thereby increasing ferroptosis sensitivity in bladder cancer cells. Collectively, this study demonstrates that P. distasonis-derived 3-IAA can inhibit bladder cancer metastasis and proliferation, highlighting the AhR-FASN axis as a promising therapeutic target to inhibit bladder cancer progression.

Indexed as

Fatty Acid Synthase, Type IFerroptosisIndoleacetic AcidsPhospholipidsReceptors, Aryl HydrocarbonUrinary Bladder NeoplasmsAnimalsCell Line, TumorCell ProliferationFemaleGastrointestinal MicrobiomeHumansMaleMiceFASN protein, humanFatty Acid Synthase, Type Iindoleacetic acidIndoleacetic AcidsPhospholipidsReceptors, Aryl Hydrocarbonaryl hydrocarbon receptorbladder cancerferroptosisindole‐3‐aceticParabacteroides distasonis

Identifiers

PMID40557796
PMCPMC12442663

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.